Drugline is a fortnightly electronic drug bulletin for health professionals.
Scroll

Drugline

Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.

Trastuzumab Deruxtecan on the PBS

Drugline Volume 485

Trastuzumab deruxtecan has been added to the Pharmaceutical Benefits Scheme (PBS) for the treatment of metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer. Around 15-20% of all breast cancers are HER2 positive,…

Read more

Baclofen Safety Update

Drugline Volume 484

The Therapeutic Goods Administration (TGA) has published a safety alert regarding the use of high doses of baclofen. This alert has been issued following recent coronial inquiries into two deaths. Baclofen is a skeletal…

Read more

Oral Azacitidine on the PBS

Drugline Volume 483

Azacitidine tablets are now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of acute myeloid leukaemia (AML) following intensive induction chemotherapy. The safety and efficacy of azacitidine tablets in this setting was…

Read more

Enzalutamide for Metastatic Hormone-Sensitive Prostate Cancer

Drugline Volume 482

The Pharmaceutical Benefits Scheme (PBS) listing for enzalutamide has recently been expanded. Enzalutamide is an oral inhibitor of androgen receptor signalling. It is now subsidised for the treatment of metastatic hormone-sensitive prostate cancer, in…

Read more

Darolutamide and Liver Test Abnormalities

Drugline Volume 481

The darolutamide product information has recently been updated to include information about hepatotoxicity. Darolutamide is a non-steroidal androgen receptor antagonist used in the treatment of prostate cancer. In the ARAMIS trial involving 1508 men…

Read more

Patiromer on the Pharmaceutical Benefits Scheme

Drugline Volume 480

Patiromer is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of chronic hyperkalaemia. Criteria to qualify for PBS-subsidised treatment include: Stage 3-4 chronic kidney disease; Condition not adequately controlled by a…

Read more
Load More